UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug

BioMarin To Re-Engage With Process But Is Doubtful Of Outcome

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".